PMID- 34720935
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211102
IS  - 1662-6575 (Print)
IS  - 1662-6575 (Electronic)
IS  - 1662-6575 (Linking)
VI  - 14
IP  - 3
DP  - 2021 Sep-Dec
TI  - Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.
PG  - 1323-1327
LID - 10.1159/000518081 [doi]
AB  - Alectinib is the first-line targeted treatment for advanced ALK-positive 
      non-small-cell lung cancer. Although it has a relatively mild toxicity profile, 
      adverse events (AEs) do occur. We present a case of alectinib-induced bilateral 
      pleural effusions and pericardial effusion that has not previously been reported. 
      The patient developed severe dyspnea 3 months after starting alectinib. He 
      underwent thorough clinical examination including evaluations of heart function. 
      The heart function was normal. There was no sign of pneumonitis or progressive 
      disease on the CT scans. Cytology samples of the pleural fluid from multiple 
      thoracocenteses were examined and showed no malignant cells. Next-generation 
      sequencing (NGS) analysis of circulating tumor DNA from sequential blood samples 
      was also carried out. NGS identified no known driver mutations associated with 
      the effusions. Hence, the effusions were suspected to be an alectinib-induced AE. 
      Alectinib was withdrawn, and the patient commenced brigatinib. The effusions 
      subsequently regressed.
CI  - Copyright (c) 2021 by S. Karger AG, Basel.
FAU - Ulhoi, Maiken Parm
AU  - Ulhoi MP
AD  - Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
FAU - Sorensen, Boe Sandahl
AU  - Sorensen BS
AD  - Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
FAU - Meldgaard, Peter
AU  - Meldgaard P
AD  - Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
LA  - eng
PT  - Case Reports
DEP - 20210916
PL  - Switzerland
TA  - Case Rep Oncol
JT  - Case reports in oncology
JID - 101517601
PMC - PMC8525301
OTO - NOTNLM
OT  - Alectinib
OT  - Non-small-cell lung cancer
OT  - Pericardial effusion
OT  - Pleural effusion
COIS- The authors have no conflicts of interest to declare.
EDAT- 2021/11/02 06:00
MHDA- 2021/11/02 06:01
PMCR- 2021/09/16
CRDT- 2021/11/01 09:09
PHST- 2021/06/09 00:00 [received]
PHST- 2021/06/18 00:00 [accepted]
PHST- 2021/11/01 09:09 [entrez]
PHST- 2021/11/02 06:00 [pubmed]
PHST- 2021/11/02 06:01 [medline]
PHST- 2021/09/16 00:00 [pmc-release]
AID - cro-0014-1323 [pii]
AID - 10.1159/000518081 [doi]
PST - epublish
SO  - Case Rep Oncol. 2021 Sep 16;14(3):1323-1327. doi: 10.1159/000518081. eCollection 
      2021 Sep-Dec.